Document is current
Any future updates will be listed below
-
Authors
Ferri, Nicola https://orcid.org/0000-0001-8898-7441
De Martin, Sara
Stuart, James
Traversa, Sergio
Folli, Franco
Pappagallo, Marco
O’Gorman, Cedric
Guidetti, Clotilde
Mattarei, Andrea
Inturrisi, Charles E.
Manfredi, Paolo L.
- License Information
-
More Information
Article History
Accepted: 2 November 2023
First Online: 27 November 2023
Declarations
:
: This research was sponsored by Relmada Therapeutics, Inc., Coral Gables, FL, USA.
: Sara De Martin received personal fees from Relmada Therapeutics and from Aesculapius Farmaceutici. Marco Pappagallo received personal fees from Relmada Therapeutics during this study, he holds stock ownership with Acadia, and he has received personal fees from Overlook Medical Center. Andrea Mattarei and Franco Folli received personal fees from Relmada Therapeutics. Sergio Traversa, Charles E. Inturrisi, and Paolo L. Manfredi received personal fees and or held stock ownership from Relmada Therapeutics. Sergio Traversa is an employee of Relmada Therapeutics. Paolo L. Manfredi and Charles E. Inturrisi are inventors on patents related to esmethadone. Clotilde Guidetti has received personal fees from MGGM Therapeutics. James Stuart received fees from Relmada as a paid consultant.
: Not applicable.
: Not applicable.
: Not applicable.
: The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.
: Not applicable.
